PE20180200A1 - Anticuerpos anti-transtiretina - Google Patents

Anticuerpos anti-transtiretina

Info

Publication number
PE20180200A1
PE20180200A1 PE2017001286A PE2017001286A PE20180200A1 PE 20180200 A1 PE20180200 A1 PE 20180200A1 PE 2017001286 A PE2017001286 A PE 2017001286A PE 2017001286 A PE2017001286 A PE 2017001286A PE 20180200 A1 PE20180200 A1 PE 20180200A1
Authority
PE
Peru
Prior art keywords
ttr
antibodies
transtiretin
accumulation
amyloidosis
Prior art date
Application number
PE2017001286A
Other languages
English (en)
Inventor
Avijit Chakrabartty
Tarlochan S Nijjar
Jeffrey N Higaki
Original Assignee
Prothena Biosciences Ltd
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Univ Health Network filed Critical Prothena Biosciences Ltd
Publication of PE20180200A1 publication Critical patent/PE20180200A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion proporciona anticuerpos que se enlazan especificamente a transtiretina (TTR). estos anticuerpos son utiles para el tratamiento o profilaxis de efectos de enfermedades o trastornos asociados con la acumulacion de TTR o la acumulacion de depositos de TTR (por ejemplo, amiloidosis de TTR). Los anticuerpos tambien pueden utilizarse para diagnosticar la amiloidosis e inhibicion de TTR o reducir la agregacion de TTR, entre otras aplicaciones
PE2017001286A 2015-01-28 2016-01-28 Anticuerpos anti-transtiretina PE20180200A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562109001P 2015-01-28 2015-01-28
US201562266557P 2015-12-11 2015-12-11

Publications (1)

Publication Number Publication Date
PE20180200A1 true PE20180200A1 (es) 2018-01-31

Family

ID=55361912

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001286A PE20180200A1 (es) 2015-01-28 2016-01-28 Anticuerpos anti-transtiretina

Country Status (20)

Country Link
US (1) US20160257736A1 (es)
EP (1) EP3250594B1 (es)
JP (2) JP6875280B2 (es)
KR (1) KR102619359B1 (es)
CN (1) CN107428822B (es)
AU (1) AU2016210887B2 (es)
BR (1) BR112017016324A2 (es)
CA (1) CA2974911A1 (es)
CO (1) CO2017008469A2 (es)
CU (1) CU24532B1 (es)
EA (1) EA036048B1 (es)
ES (1) ES2905311T3 (es)
MX (1) MX2017009804A (es)
MY (1) MY193674A (es)
PE (1) PE20180200A1 (es)
SA (1) SA517381991B1 (es)
SG (1) SG11201706125QA (es)
TW (2) TWI781507B (es)
WO (1) WO2016120809A1 (es)
ZA (1) ZA201705662B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI781507B (zh) * 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
EP3478716A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478714A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) * 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3691626A4 (en) * 2017-10-06 2021-06-30 Prothena Biosciences Limited METHODS OF DETECTION OF TRANSTHYRETINE
KR20200074956A (ko) * 2017-10-06 2020-06-25 프로테나 바이오사이언시즈 리미티드 항-트랜스타이레틴 항체
BR112020010483A2 (pt) 2017-11-29 2020-10-20 Prothena Biosciences Limited formulação liofilizada de um anticorpo monoclonal contra transtirretina
CN113874510A (zh) 2019-06-04 2021-12-31 瑞泽恩制药公司 包括具有β滑移突变的人源化TTR基因座的非人动物和使用方法
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
DE60045319D1 (de) 1999-02-05 2011-01-13 Samsung Electronics Co Ltd Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
CA2471849A1 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
CA2507664C (en) 2002-11-29 2010-09-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
PL1820022T3 (pl) 2004-11-10 2009-11-30 Boehringer Ingelheim Pharma Zastosowanie analizy metodą cytometrii przepływowej w optymalizacji strategii dla banków komórek jajnika chińskiego chomika
EP2808020A1 (en) 2006-04-21 2014-12-03 The Government Of The United States, As Represented by The Secretary Of Health And Human Services Beta-Amyloid Pet Imaging Agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
DK2126093T3 (da) 2007-03-02 2013-01-07 Boehringer Ingelheim Pharma Forbedring af proteinfremstilling
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
WO2010030203A1 (en) 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
WO2014124334A2 (en) * 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體

Also Published As

Publication number Publication date
ZA201705662B (en) 2018-08-29
CN107428822B (zh) 2021-11-23
EA201791711A1 (ru) 2017-11-30
KR20170120607A (ko) 2017-10-31
US20160257736A1 (en) 2016-09-08
AU2016210887B2 (en) 2021-11-04
WO2016120809A1 (en) 2016-08-04
EP3250594B1 (en) 2021-11-17
KR102619359B1 (ko) 2024-01-02
AU2016210887A1 (en) 2017-08-10
JP7219928B2 (ja) 2023-02-09
TW201636372A (zh) 2016-10-16
JP6875280B2 (ja) 2021-05-26
CU20170096A7 (es) 2018-03-13
TW202118782A (zh) 2021-05-16
MY193674A (en) 2022-10-24
CU24532B1 (es) 2021-07-02
EP3250594A1 (en) 2017-12-06
ES2905311T3 (es) 2022-04-07
JP2018509889A (ja) 2018-04-12
MX2017009804A (es) 2018-08-15
CN107428822A (zh) 2017-12-01
BR112017016324A2 (pt) 2018-03-27
CA2974911A1 (en) 2016-08-04
TWI781507B (zh) 2022-10-21
TWI718121B (zh) 2021-02-11
JP2021129562A (ja) 2021-09-09
SA517381991B1 (ar) 2021-12-13
SG11201706125QA (en) 2017-08-30
CO2017008469A2 (es) 2018-01-16
EA036048B1 (ru) 2020-09-18

Similar Documents

Publication Publication Date Title
PE20180200A1 (es) Anticuerpos anti-transtiretina
CO2017008476A2 (es) Anticuerpos anti-transtiretina
CO2017008482A2 (es) Anticuerpos anti-transtiretina
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
DOP2017000150A (es) Anticuerpos anti-cd 38 para el tratamiento de leucemia mieloides aguda
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
CU20200021A7 (es) Anticuerpos anti-transtiretina
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
WO2018007924A3 (en) Anti-transthyretin antibodies
CR20170005A (es) Derivados de insoindolina
WO2018007923A3 (en) Anti-transthyretin antibodies
EA201891299A1 (ru) Терапевтические антитела к cd9
CO2020005420A2 (es) Compuestos antibacterianos
BR112015019924A2 (pt) métodos e composições para tratar leucemia
BR112016015578A2 (pt) Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2
SV2016005353A (es) Forma polimã“rfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento del alzhã‰imer
AR103549A1 (es) Anticuerpos anti-transtiretina
AR113345A1 (es) Anticuerpos anti-transtiretina
AR103548A1 (es) Anticuerpos anti-transtiretina
AR105955A1 (es) Método para producir una piridinacarboxamida
BR112018007290A2 (pt) minha patente 1